

- 1 Full title: The effect of smoking on multiple sclerosis: a mendelian randomization study
- 2 Short title: Smoking exposure and risk multiple sclerosis
- 3 Ruth E Mitchell^{1,2*}, Kirsty Bates^{2*}, Robyn E Wootton^{1,3,4}, Adil Harroud^{6,7}, J. Brent
- 4 Richards^{8,9,10,11,12}, George Davey Smith^{1,2}, Marcus R Munafò^{1,4,5}
- 5 1. Medical Research Council Integrative Epidemiology Unit, University of Bristol, Oakfield
- 6 House, Oakfield Grove, Bristol BS8 2BN, UK
- 7 2. Population Health Sciences, Bristol Medical School, University of Bristol, UK
- 8 3. Avon & Wiltshire Mental Health Partnership Trust, UK
- 9 4. School of Psychological Science, University of Bristol, Bristol BS8 1TU, UK
- 10 5. NIHR Biomedical Research Centre at the University Hospitals Bristol NHS Foundation
- 11 Trust and the University of Bristol, BS8 2BN
- 12 6. Department of Neurology, University of California San Francisco, CA, USA
- 13 7. Weill Institute for Neurosciences, University of California San Francisco, CA, USA
- 14 8. Department of Human Genetics, McGill University, Montreal, Quebec, Canada
- 15 9. Centre for Clinical Epidemiology, Department of Epidemiology, Lady Davis Institute for
- 16 Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
- 17 10. Department of Medicine, McGill University Montreal, Quebec, Canada
- 18 11. Department of Human Genetics, McGill University, Montreal, Quebec, Canada
- 19 12. Department of Twin Research and Genetic Epidemiology, King's College London, UK
- 20 *These authors contributed equally
- 21 Correspondence should be addressed to Ruth Mitchell (email: r.mitchell@bristol.ac.uk).

22 **Abstract**

23 The causes of multiple sclerosis (MS) remain unknown. Smoking has been associated with
24 MS in observational studies and is often thought of as an environmental risk factor. We used
25 two-sample Mendelian Randomization (MR) to examine whether this association is causal
26 using genetic variants identified in genome-wide association studies (GWAS) as associated
27 with smoking. We assessed both smoking initiation and lifetime smoking behaviour (which
28 captures smoking duration, heaviness and cessation). There was very limited evidence for a
29 meaningful effect of smoking on MS susceptibility was measured using summary statistics
30 from the International Multiple Sclerosis Genetics Consortium (IMSGC) meta-analysis,
31 including 14,802 cases and 26,703 controls. There was no clear evidence for an effect of
32 smoking on the risk of developing MS (smoking initiation: odds ratio [OR] 1.03, 95%
33 confidence interval [CI] 0.92-1.61; lifetime smoking: OR 1.10, 95% CI 0.87-1.40). These
34 findings suggest that smoking does not have a detrimental consequence on MS susceptibility.
35 Further work is needed to determine the causal effect of smoking on MS progression.

36

37 **Background**

38 Smoking is an avoidable environmental cause to many life-threatening diseases such as lung
39 cancer, heart and respiratory disorders (1,2). There is emerging evidence linking cigarette
40 smoke to conditions negatively affecting the central nervous system (CNS), like multiple
41 sclerosis (MS) (3,4). MS is a chronic neurological disorder causing autoimmune breakdown
42 of the myelin sheath surrounding axons in the CNS (5). The disease is characterised by
43 periods of disease activity followed by remission and/or progressive neurological decline,
44 resulting in increasing disability (6). Like most autoimmune conditions, there is no known
45 specific cause; however, we know there is an interaction between genetic and environmental

46 factors in susceptible individuals, that go on to develop the disorder (7). Unfortunately, there
47 is no cure for MS(8), and people diagnosed often live with extreme disability (9). There are
48 emerging treatments aimed at modifying the disease course (10), but they are not universally
49 effective particularly with regards to the progressive form of the disease. Therefore, it is
50 important to continue targeting prevention by means of establishing causal links.

51 Evidence from observational epidemiological studies suggests that smoking increases MS
52 risk (11). It is hypothesised from experimental studies that exposure to chemicals in cigarette
53 smoke alter the immune cell balance in the lung (12,13) which in turn can lead to generalised
54 pro-inflammatory effects that trigger autoimmunity (14,15), in genetically susceptible
55 individuals (16,17). In addition, cigarette chemicals contribute mechanistically to MS
56 pathobiology. Specifically, nicotine increases the permeability of the blood-brain barrier (18);
57 cyanide contributes to demyelination (19); and nitric oxide causes degeneration of axons
58 (20). There is evidence for an association between smoking and worsening symptoms,
59 number of relapses, lesion load on MRI, brain atrophy rate (15) and the rapidity of disability
60 progression in MS patients (4,21,22).

61 However, it is hard to make causal inferences from observational studies which can be biased
62 by issues of reverse causation and residual confounding. One method which can be used to
63 reduce these sources of bias is Mendelian Randomization (MR) (23). MR can be
64 implemented through instrumental variable analysis that uses genetic variants to proxy the
65 exposure (e.g, smoking) and estimate a causal effect of that exposure on the outcome (e.g,
66 MS). The MR method makes three important assumptions: 1) the genetic variants must
67 robustly predict the exposure, 2) the genetic variants must not be associated with any
68 confounders and 3) the genetic variants must only affect the outcome through the exposure
69 (24). To satisfy the first assumption we selected the most recently available genetic
70 instruments from previously conducted genome-wide association studies (GWAS) associated

71 with smoking behaviour (smoking initiation (25) and lifetime smoking (26)) that can be
72 implemented in a two-sample MR context (Fig 1). The latter two assumptions can be violated
73 by horizontal pleiotropy which occurs when the genetic variants affect the outcome other
74 than through the exposure. We test for this possibility using multiple sensitivity analyses.

75 **Fig 1. Directed acyclic graph of the Mendelian randomization framework investigating**
76 **the causal relationship between smoking and multiple sclerosis.** Instrumental variable
77 assumptions: IV1: the instruments must be associated with the exposure; IV2: the instruments
78 must influence MS only through smoking; IV3: the instruments must not associate with
79 measured or unmeasured confounders in the smoking to MS relationship.

80 **Results**

81 **Smoking initiation**

82 The inverse-variance weighted MR estimate (OR 1.03, 95% confidence interval (CI) 0.92 -
83 1.16) revealed no strong evidence for a causal effect of the genetic risk of smoking initiation
84 on incidence of MS (Fig 3). This was consistent across all MR methods employed, providing
85 further support for the result as each MR method has different assumptions and therefore tests
86 for different violations of those assumptions. Indeed, the weighted median and weighted
87 mode only allow SNPs in the largest homogeneous cluster to contribute to the overall
88 estimate and provide estimates with confidence intervals overlapping the null (Fig 3 and
89 Supplementary Fig 1). The 371 SNPs used as genetic proxies for smoking initiation (Fig 2a
90 and Supplementary Table 1) had an F statistic of 44.90 indicating a strong instrument and that
91 weak instrument bias was unlikely to be influencing the effect estimates. There was evidence
92 of heterogeneity with a large Cochran's Q statistic of 559.48, $p=6.65 \times 10^{-6}$ and the MR-
93 PRESSO global test value of 562.12, $p<0.000125$. However, this not indicative of directional
94 horizontal pleiotropy given the consistent MR Egger estimate (OR 1.13, 95% CI 0.67 to

95 1.91), small intercept (0.0017, $p=0.73$) and symmetrical funnel plot (Supplementary Fig 2).
96 Similarly, MR-RAPS is robust to systematic and idiosyncratic pleiotropy, accounting for
97 weak instruments, pleiotropy and extreme outliers, and gave a similar causal estimate (OR
98 1.05, 95% CI 0.93 to 1.17). Furthermore, MR-PRESSO removes individual SNPs that
99 contribute to heterogeneity disproportionately more than expected in order to reduce
100 heterogeneity. The MR-PRESSO outlier corrected causal estimate was 1.040 (95% CI 1.040
101 to 1.041). Therefore, the second IV assumption (known as the exclusion restriction
102 assumption) of MR has not been violated and directional pleiotropy is unlikely to be biasing
103 the estimates, even though the outlier removal automatically leads to over precise estimates.
104 Leave-one-out and single SNP analyses (Supplementary Fig 3 and 4) were conducted as
105 sensitivity tests sequentially omitting one SNP at a time and performing MR using a single
106 SNP respectively to assess the sensitivity of the results to individual variants. These indicated
107 that there is not a single SNP driving the association whose effect is being masked in the
108 overall analysis. The exclusion of exposure variants located within the MHC did not alter the
109 null association between smoking initiation and incidence of MS (Supplementary Table 2).

110 **Fig 2. Flowchart for selection of genetic variants associated with smoking initiation (A)**
111 **and lifetime smoking (B).** Abbreviations: GSCAN: GWAS & Sequencing Consortium of
112 Alcohol and Nicotine use; GWAS: Genome-Wide Association Study; LD: Linkage
113 Disequilibrium; MS: multiple sclerosis; IMSGC: International Multiple Sclerosis Genetics
114 Consortium; MR: Mendelian Randomization; SNP: Single-Nucleotide Polymorphism.

115 **Fig 3: Two-sample Mendelian Randomization estimates of the association between**
116 **smoking initiation and incidence of multiple sclerosis.** Odds ratios are expressed per unit
117 increase in log odds of ever smoking regularly (smoking initiation). MR: Mendelian
118 Randomization; OR=Odds Ratio; CI=Confidence Intervals; p.val: p value.

119 **Lifetime smoking**

120 There was no clear evidence for a causal effect of the genetic risk of lifetime smoking on
121 incidence of MS (Fig 4). The 125 SNPs used as genetic proxies for lifetime smoking (Fig 2b
122 and Supplementary Table 3) had an F statistic of 44.05 indicating a strong instrument that is
123 unlikely to cause the effect estimates to be affected by weak instrument bias. The inverse-
124 variance weighted MR analysis estimate (OR 1.10, 95% CI 0.87 to 1.40) revealed no strong
125 evidence for a causal effect of the genetic risk of lifetime smoking on incidence of MS and
126 was consistent across all MR methods employed (Fig 4 and Supplementary Fig 5). There was
127 evidence of heterogeneity among the individual SNP effect estimates for lifetime smoking
128 with a large Cochran Q statistic (156.18, $p=0.02$) and MR-PRESSO global test estimate of
129 158.4895, $p=0.03$. However, this was not supported by the symmetrical funnel plot
130 (Supplementary Fig 6) nor by any outliers detected in the MR-PRESSO test. Furthermore, the
131 small MR Egger intercept (-0.003 , $p=0.69$) and consistent MR Egger estimate (OR 1.34, 95%
132 CI 0.49 to 3.65) suggests that the magnitude of potential bias from directional pleiotropy is
133 low. Furthermore, there was no single SNP driving the association whose effect is being
134 masked in the overall estimate as demonstrated by the leave-one-out and single SNP
135 sensitivity analyses (Supplementary Fig 7 and 8). MR excluding the lifetime smoking
136 associated variant located within the MHC region yielded consistent results overlapping the
137 null (Supplementary Table 4).

138 **Figure 4: Two-sample Mendelian Randomization estimates of the association between**
139 **lifetime smoking and incidence of multiple sclerosis.** Odds ratios are expressed per 1
140 standard deviation increase of the lifetime smoking index. MR: Mendelian Randomization;
141 OR=Odds Ratio; CI=Confidence Intervals; p.val: p value.

142

143 A bidirectional analysis shows that there was no clear evidence that a genetic predisposition
144 to MS is associated with either smoking initiation or lifetime smoking (Supplementary Table
145 5 and 7). MR of MS associated variants located within the MHC region yielded consistent
146 results overlapping the null (Supplementary Table 6 and 8).

147

148 **Discussion**

149 This study uses the MR method to estimate the causal effect of smoking on risk for MS.

150 Using a two-sample MR design in 14,802 MS cases and 26,703 controls, we found little

151 evidence that both genetically predicted smoking initiation and lifetime smoking are

152 associated with MS risk. These findings suggest that smoking is not a clear environmental

153 risk factor for MS susceptibility and are in line with a recent independent study (27).

154 Although a small effect cannot be entirely excluded, the relatively narrow confidence

155 intervals, particularly for smoking initiation, make a clinically relevant effect less likely.

156 This contradicts previously reported observational studies that show an association with MS

157 risk among smokers, compared to non-smokers, of a meta-analysed effect estimate odds ratio

158 of 1.5 (4,11). The studies included limitations such as self-report MS diagnosis (28),

159 participation rate less than 80% (29–31) and loss to follow up (32). Additionally,

160 observational studies may have heterogenous results due to how smoking status was defined

161 (11). The strength of association and causality between smoking and MS risk has been

162 suggested due to a dose-dependent relationship in duration and intensity of smoking (4,33) as

163 well as from the interaction between compounds present in cigarettes and specific genetic

164 HLA variants, which include the presence of HLA-DRB1*15, the absence of HLA-A*0201

165 (34) and specific N-acetyltransferase 1 (NAT1) polymorphisms (35). These genetic variants

166 facilitated epitope cross-reactivity and activation of T cells and smoking may strongly

167 influence the risk of MS observed with these HLA genotypes. However, other studies have
168 failed to replicate this interaction (36,37). In order to test this interaction in an MR casual
169 inference context, a factorial MR design in MS patients with and without those alleles would
170 be required. This was not possible in the present study due to the use of GWAS summary
171 statistics. Observational estimates may have also been biased by residual or unmeasured
172 confounding from factors influencing both smoking status and MS. For example, co-
173 morbidities and socioeconomic status may influence the likelihood of being a smoker and
174 having MS (15,38).

175 Reverse causation could also partly explain the discrepancy between our MR results and
176 observational studies especially as MS onset may occur long before the first clinical
177 symptoms (39). For instance, this prodromal phase is characterized in part by a higher risk of
178 depression and anxiety up to 10 years prior to MS diagnosis (40), and these in turn are
179 associated with a higher rate of smoking. This study sought to reduce bias from confounding
180 and reverse causation by using a MR design given genetic variants are much less associated
181 with confounders than directly measured environmental exposures (41) (here smoking) and
182 genetic variants are fixed over our lifetime ensuring directionality of effect. This is a major
183 strength of this study in establishing causality in the relationship between smoking and MS
184 risk. Additionally, MR reverse direction MR was performed and shows that reverse causation
185 is unlikely to be playing a role. A further strength of this study is the use of robust genetic
186 instruments which are strong predictors of smoking behaviour. Finally, we used multiple MR
187 methods and sensitivity analyses to test for bias from directional horizontal pleiotropy. Our
188 estimates were consistent across these multiple methods, strengthening our conclusions.

189 The current study cannot inform us about the effects of smoking on MS symptom severity,
190 disability or progression of disease. Indeed, smoking shows an association with disease
191 progression, disease activity (new lesions on magnetic resonance imaging (MRI); clinical

192 relapse rates) and brain atrophy (15). Observational studies have shown an association
193 between smoking and progression from relapsing remitting MS to secondary progressive MS
194 with a dose-response relationship (42–46) as well as a faster rate increasing Expanded
195 Disability Status Scale (EDSS) (22). However, more research in this area is needed to for a
196 definitive conclusion of an effect and specific mechanisms of action. As new methods are
197 being developed to assess disease progression using MR (47), when a GWAS of MS
198 progression becomes available, future studies should explore the association between
199 smoking and the different measures of MS progression in a MR framework.

200 The instrument predicting smoking initiation and lifetime smoking were broadly distinct
201 (only 9 SNPs overlapping). The measure of lifetime smoking exposure takes into account
202 smoking status and, among ever smokers, duration, heaviness and cessation. Although our
203 lifetime smoking instrument captured smoking heaviness in part, however we were unable to
204 explore whether there was a dose-response relationship between the number of cigarettes
205 smoked and the likelihood of developing MS given we were unable to stratify the MS GWAS
206 by smoking status. Most, but not all (30,48,49), evidence to date seems to suggest that there
207 is a positive correlation between the amount smoked and the severity of illness
208 (4,31,37,43,50–53). It might be that rather than a causal relationship between smoking and
209 MS risk, that smoking instead accelerates the disease process in those that would have
210 already developed MS.

211 Limitations of this study are, firstly, that although we assessed pleiotropy using MR methods
212 that account for pleiotropic effects, pleiotropy can only be addressed indirectly, and some
213 SNPs may relate to MS risk through pathways other than smoking. We did not find evidence
214 for bias for horizontal pleiotropy using the MR Egger intercept test nor the funnel plots which
215 did not reveal evidence of directional, or unbalanced, pleiotropy. Secondly, this study was a

216 two-sample MR using MS meta-analysis summary statistics and therefore this does not allow
217 for gene-environment interaction or sex stratified analysis.

218 In conclusion, we find no clear evidence for a causal effect of smoking on the risk of
219 developing MS. Previous observational results may have been due to confounding factors,
220 which we have avoided through our analysis. Future research should focus on the effect of
221 smoking on the disease course of MS and its effect on progression.

222

223 **Methods**

224 **Genetic instruments for smoking**

225 *Smoking initiation.* We used the most recent GWAS of smoking initiation from the GWAS &
226 Sequencing Consortium of Alcohol and Nicotine use (GSCAN) consortium which identified
227 378 conditionally independent genome-wide significant SNPs in a sample of 1,232,091
228 individuals of European ancestry. These genetic variants explain 2% of the variance in
229 smoking initiation(25).

230 *Lifetime smoking.* In order to incorporate measures of smoking heaviness without having to
231 stratify on smoking status (which is not possible in the two-sample MR context without a
232 stratified GWAS of MS), we used the GWAS of lifetime smoking conducted in 462,690
233 individuals of European ancestry from the UK Biobank (26). Lifetime smoking is a
234 combination of smoking initiation, duration, heaviness and cessation described in detail
235 elsewhere (26). This GWAS identified 126 independent genome-wide significant SNPs that
236 explain 0.36% of the variance(26).

237 **Genetic variants associated with multiple sclerosis**

238 Effect estimates and standard errors for smoking associated SNPs on MS susceptibility were
239 obtained from the summary statistics of the discovery cohorts of the latest International
240 Multiple Sclerosis Genetics Consortium (IMSGC) meta-analysis, including 14,802 cases and
241 26,703 controls (54). All details relating to demographic characteristics, MS case
242 ascertainment and eligibility criteria for the meta-analysis can be found in the original
243 publication (54). For SNPs not available in the IMSGC dataset, we identified proxy SNPs in
244 high linkage disequilibrium ($r^2 > 0.8$) using an online tool LDlink
245 [<https://ldlink.nci.nih.gov/?tab=ldproxy>], giving a total of 371 SNPs for smoking initiation
246 instrument and 125 SNPs for lifetime smoking (Figure 2 and Supplementary Table 1 and 2).

247

248 **Mendelian Randomization analyses**

249 A two sample MR was undertaken to obtain effect estimates of genetically predicted smoking
250 on MS susceptibility, using both initiation and lifetime proxy measures. MR and sensitivity
251 analyses were performed in R (version 3.5.1) using the TwoSampleMR R package
252 (<https://mrcieu.github.io/TwoSampleMR/>) (55) with effect estimates compared across five
253 different methods: inverse variance weighted (IVW); MR Egger (56); weighted median (57);
254 weighted mode (58); robust adjusted profile score (RAPS) (59); pleiotropy residual sum and
255 outlier (PRESSO) (60). Given the different assumptions that each of these methods make
256 about the nature of pleiotropy, consistency in the point estimate across the methods
257 strengthens causal evidence (61). The IWV method is the main analysis and the other
258 methods provide sensitivity analyses. Instrumental variable analysis of MR is based on a ratio
259 of the regressions of the genetic instrument-outcome association (weighted smoking
260 associated SNPs with MS from IMSGC) on the genetic instrument-exposure association
261 (smoking associated SNPs with smoking initiation or lifetime smoking in the independent
262 smoking GWASs). For smoking initiation, the odds ratios are expressed per unit increase in

263 log odds of ever smoking regularly (smoking initiation); for lifetime smoking, the odds ratios
264 are expressed per 1 standard deviation increase of the lifetime smoking index.

265 Additional sensitivity analyses were performed in order to formally test for potential
266 violations of MR assumptions. The mean F statistic was calculated as an indicator of
267 instrument strength (a value of >10 indicates a strong instrument) and the Cochran's Q
268 statistic was assessed as a measure of heterogeneity for the IVW method to estimate whether
269 the individual SNP effects of smoking on MS were inconsistent. The MR Egger intercept was
270 assessed to detect directional pleiotropy where the genetic instruments would be influencing
271 MS through another pathway other than smoking. To identify potentially influential SNPs,
272 which could be driven for example by horizontal pleiotropy, we used leave-one-out and
273 single-SNP MR analyses. Additionally, due to the strong genetic signal for MS within the
274 MHC region and high potential for pleiotropy, MR analysis excluding exposure variants
275 located within the extended major histocompatibility (MHC) region was performed (defined
276 as base positions 24,000,000 to 35,000,000 on chromosome 6 [GRCh37].

277

278

279 **References**

- 280 1. O’Keeffe LM, Taylor G, Huxley RR, Mitchell P, Woodward M, Peters SAE. Smoking
281 as a risk factor for lung cancer in women and men: A systematic review and meta-
282 analysis. Vol. 8, *BMJ Open*. BMJ Publishing Group; 2018.
- 283 2. Aune D, Schlesinger S, Norat T, Riboli E. Tobacco smoking and the risk of sudden
284 cardiac death: a systematic review and meta-analysis of prospective studies. *Eur J*
285 *Epidemiol* [Internet]. 2018 Jun 7 [cited 2020 Jan 20];33(6):509–21. Available from:
286 <http://link.springer.com/10.1007/s10654-017-0351-y>
- 287 3. George MF, Briggs FBS, Shao X, Gianfrancesco MA, Kockum I, Harbo HF, et al.
288 Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies.
289 *Neurol Genet* [Internet]. 2016 Aug [cited 2017 Mar 28];2(4):e87. Available from:
290 <http://www.ncbi.nlm.nih.gov/pubmed/27540591>
- 291 4. Poorolajal J, Bahrami M, Karami M, Hooshmand E. Effect of smoking on multiple
292 sclerosis: A meta-analysis. *J Public Heal (United Kingdom)*. 2017 Jun 1;39(2):312–20.
- 293 5. Dobson R, Giovannoni G. Multiple sclerosis – a review [Internet]. Vol. 26, *European*
294 *Journal of Neurology*. Blackwell Publishing Ltd; 2019 [cited 2020 Mar 31]. p. 27–40.
295 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/30300457>
- 296 6. Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis.
297 *Nat Rev Dis Prim*. 2018 Dec 1;4(1):1–27.
- 298 7. Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and
299 environmental risk factors for multiple sclerosis. Vol. 13, *Nature Reviews Neurology*.
300 Nature Publishing Group; 2016. p. 26–36.
- 301 8. Gohil K. Multiple sclerosis: Progress, but no cure. Vol. 40, P and T. *Medi Media USA*

- 302 Inc; 2015. p. 604–5.
- 303 9. Kister I, Chamot E, Salter AR, Cutter GR, Bacon TE, Herbert J. Disability in multiple
304 sclerosis: A reference for patients and clinicians. *Neurology*. 2013 Mar
305 12;80(11):1018–24.
- 306 10. Scolding N, Barnes D, Cader S, Chataway J, Chaudhuri A, Coles A, et al. Association
307 of British Neurologists: Revised (2015) guidelines for prescribing disease-modifying
308 treatments in multiple sclerosis. *Pract Neurol*. 2015 Jan 8;15(4):273–9.
- 309 11. Degelman ML, Herman KM. Smoking and multiple sclerosis: A systematic review and
310 meta-analysis using the Bradford Hill criteria for causation. Vol. 17, *Multiple Sclerosis
311 and Related Disorders*. Elsevier B.V.; 2017. p. 207–16.
- 312 12. Ammitzbøll C, Börnsen L, Romme Christensen J, Ratzner R, Romme Nielsen B,
313 Søndergaard HB, et al. Smoking reduces circulating CD26 hi CD161 hi MAIT cells in
314 healthy individuals and patients with multiple sclerosis. *J Leukoc Biol*. 2017
315 May;101(5):1211–20.
- 316 13. Makrygiannakis D, Hermansson M, Ulfgren AK, Nicholas AP, Zendman AJW,
317 Eklund A, et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in
318 human lungs and increases citrullination in BAL cells. *Ann Rheum Dis* [Internet].
319 2008 Oct [cited 2020 Apr 2];67(10):1488–92. Available from:
320 <http://www.ncbi.nlm.nih.gov/pubmed/18413445>
- 321 14. Odoardi F, Sie C, Streyll K, Ulaganathan VK, Schläger C, Lodygin D, et al. T cells
322 become licensed in the lung to enter the central nervous system. *Nature* [Internet].
323 2012 Aug 30 [cited 2020 Apr 2];488(7413):675–9. Available from:
324 <http://www.ncbi.nlm.nih.gov/pubmed/22914092>

- 325 15. Rosso M, Chitnis T. Association between Cigarette Smoking and Multiple Sclerosis: A
326 Review [Internet]. Vol. 77, JAMA Neurology. American Medical Association; 2020
327 [cited 2020 Apr 2]. p. 245–53. Available from:
328 <http://www.ncbi.nlm.nih.gov/pubmed/31841592>
- 329 16. Hedström AK, Katsoulis M, Hössjer O, Bomfim IL, Oturai A, Sondergaard HB, et al.
330 The interaction between smoking and HLA genes in multiple sclerosis: replication and
331 refinement. *Eur J Epidemiol*. 2017 Oct 1;32(10):909–19.
- 332 17. Sawcer S, Hellenthal G. The major histocompatibility complex and multiple sclerosis:
333 a smoking gun? *Brain* [Internet]. 2011 Mar [cited 2020 Jan 20];134(3):638–40.
334 Available from: [https://academic.oup.com/brain/article-](https://academic.oup.com/brain/article-lookup/doi/10.1093/brain/awq384)
335 [lookup/doi/10.1093/brain/awq384](https://academic.oup.com/brain/article-lookup/doi/10.1093/brain/awq384)
- 336 18. Chen JL, Wei L, Bereczki D, Hans FJ, Otsuka T, Acuff V, et al. Nicotine raises the
337 influx of permeable solutes across the rat blood-brain barrier with little or no capillary
338 recruitment. *J Cereb Blood Flow Metab* [Internet]. 1995 Jul 29 [cited 2020 Apr
339 2];15(4):687–98. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/7790419>
- 340 19. Philbrick DJ, Hopkins JB, Hill DC, Alexander JC, Thomson RG. Effects of prolonged
341 cyanide and thiocyanate feeding in rats. *J Toxicol Environ Health*. 1979;5(4):579–92.
- 342 20. Smith KJ, Kapoor R, Hall SM, Davies M. Electrically active axons degenerate when
343 exposed to nitric oxide. *Ann Neurol* [Internet]. 2001 Apr 1 [cited 2020 Apr
344 2];49(4):470–6. Available from: <http://doi.wiley.com/10.1002/ana.96>
- 345 21. Wingerchuk DM. Smoking: Effects on multiple sclerosis susceptibility and disease
346 progression. Vol. 5, *Therapeutic Advances in Neurological Disorders*. 2012. p. 13–22.
- 347 22. Heydarpour P, Manouchehrinia A, Beiki O, Mousavi SE, Abdolalizadeh A, Lakeh

- 348 MM, et al. Smoking and worsening disability in multiple sclerosis: A meta-analysis.
349 Acta Neurol Scand. 2018 Jul 1;138(1):62–9.
- 350 23. Davey Smith G, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology
351 contribute to understanding environmental determinants of disease?*. Int J Epidemiol
352 [Internet]. 2003 Feb [cited 2019 Jan 28];32(1):1–22. Available from:
353 <https://academic.oup.com/ije/article-lookup/doi/10.1093/ije/dyg070>
- 354 24. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal
355 inference in epidemiological studies. Hum Mol Genet [Internet]. 2014 Sep 15 [cited
356 2019 Jan 28];23(R1):R89–98. Available from: <https://academic.oup.com/hmg/article-lookup/doi/10.1093/hmg/ddu328>
- 358 25. Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, et al. Association studies of up
359 to 1.2 million individuals yield new insights into the genetic etiology of tobacco and
360 alcohol use. Vol. 51, Nature Genetics. Nature Publishing Group; 2019. p. 237–44.
- 361 26. Wootton RE, Richmond RC, Stuijzand BG, Lawn RB, Sallis HM, Taylor GMJ, et al.
362 Evidence for causal effects of lifetime smoking on risk for depression and
363 schizophrenia: a Mendelian randomisation study. Psychol Med [Internet]. 2019 Nov 6
364 [cited 2020 Jan 20];1–9. Available from:
365 <http://www.ncbi.nlm.nih.gov/pubmed/31689377>
- 366 27. Vandeborgh M, Goris A. Smoking and multiple sclerosis risk: a Mendelian
367 randomization study. J Neurol [Internet]. 2020 [cited 2020 Jun 22]; Available from:
368 <https://pubmed.ncbi.nlm.nih.gov/32529581/>
- 369 28. Riise T, Nortvedt MW, Ascherio A. Smoking is a risk factor for multiple sclerosis.
370 Neurology. 2003 Oct 28;61(8):1122–4.

- 371 29. O’Gorman C, Broadley SA. Smoking and multiple sclerosis: evidence for latitudinal
372 and temporal variation. *J Neurol*. 2014;261(9):1677–83.
- 373 30. Salzer J, Hallmans G, Nyström M, Stenlund H, Wadell G, Sundström P. Smoking as a
374 risk factor for multiple sclerosis. *Mult Scler J*. 2013;19(8):1022–7.
- 375 31. Hedström AK, Bäärnhielm M, Olsson T, Alfredsson L. Tobacco smoking, but not
376 Swedish snuff use, increases the risk of multiple sclerosis. *Neurology*. 2009 Sep
377 1;73(9):696–701.
- 378 32. Thorogood M, Hannaford PC. The influence of oral contraceptives on the risk of
379 multiple sclerosis. *BJOG An Int J Obstet Gynaecol*. 1998;105(12):1296–9.
- 380 33. Hedström AK, Olsson T, Alfredsson L. Smoking is a major preventable risk factor for
381 multiple sclerosis. *Mult Scler*. 2016 Jul 1;22(8):1021–6.
- 382 34. Hedström AK, Sundqvist E, Bä M, Nordin N, Hillert J, Kockum I, et al. Smoking and
383 two human leukocyte antigen genes interact to increase the risk for multiple sclerosis.
384 *A J Neurol [Internet]*. [cited 2020 Apr 28]; Available from:
385 <https://academic.oup.com/brain/article-abstract/134/3/653/446931>
- 386 35. Briggs FBS, Acuna B, Shen L, Ramsay P, Quach H, Bernstein A, et al. Smoking and
387 risk of multiple sclerosis: Evidence of modification by NAT1 variants. *Epidemiology*.
388 2014;25(4):605–14.
- 389 36. Petersen ER, Oturai AB, Koch-Henriksen N, Magyar M, Sørensen PS, Sellebjerg F, et
390 al. Smoking affects the interferon beta treatment response in multiple sclerosis.
391 *Neurology*. 2018 Feb 13;90(7):e593–600.
- 392 37. Simon KC, Van Der Mei IAF, Munger KL, Ponsonby A, Dickinson J, Dwyer T, et al.
393 Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on

- 394 multiple sclerosis risk. *Neurology*. 2010;74(17):1365–71.
- 395 38. Wingerchuk DM. Smoking: Effects on multiple sclerosis susceptibility and disease
396 progression. Vol. 5, *Therapeutic Advances in Neurological Disorders*. SAGE
397 Publications; 2012. p. 13–22.
- 398 39. Disanto G, Zecca C, MacLachlan S, Sacco R, Handunnetthi L, Meier UC, et al.
399 Prodromal symptoms of multiple sclerosis in primary care. *Ann Neurol* [Internet].
400 2018 Jun 1 [cited 2020 Apr 3];83(6):1162–73. Available from:
401 <http://www.ncbi.nlm.nih.gov/pubmed/29740872>
- 402 40. M F, AE T, M G, MR M. The Association of Cigarette Smoking With Depression and
403 Anxiety: A Systematic Review. *Nicotine Tob Res*. 2017;19(1).
- 404 41. Smith GD, Ebrahim S. “Mendelian randomization”: Can genetic epidemiology
405 contribute to understanding environmental determinants of disease? Vol. 32,
406 *International Journal of Epidemiology*. 2003. p. 1–22.
- 407 42. Koch M, Van Harten A, Uyttenboogaart M, De Keyser J. Cigarette smoking and
408 progression in multiple sclerosis. *Neurology*. 2007 Oct;69(15):1515–20.
- 409 43. Sundström P, Nyström L. Smoking worsens the prognosis in multiple sclerosis. *Mult*
410 *Scler*. 2008;14(8):1031–5.
- 411 44. Healy BC, Ali EN, Guttmann CRG, Chitnis T, Glanz BI, Buckle G, et al. Smoking and
412 disease progression in multiple sclerosis. *Arch Neurol*. 2009 Jul;66(7):858–64.
- 413 45. Hernán MA, Jick SS, Logroscino G, Olek MJ, Ascherio A, Jick H. Cigarette smoking
414 and the progression of multiple sclerosis. *Brain* [Internet]. 2005 Jun [cited 2020 Apr
415 3];128(Pt 6):1461–5. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15758034>
- 416 46. Roudbari SA, Ansar MM, Yousefzad A. Smoking as a risk factor for development of

- 417 Secondary Progressive Multiple Sclerosis: A study in IRAN, Guilan. *J Neurol Sci.*
418 2013 Jul 15;330(1–2):52–5.
- 419 47. Paternoster L, Tilling K, Davey Smith G. Genetic epidemiology and Mendelian
420 randomization for informing disease therapeutics: Conceptual and methodological
421 challenges. Barsh GS, editor. *PLOS Genet* [Internet]. 2017 Oct 5 [cited 2017 Dec
422 12];13(10):e1006944. Available from:
423 <http://www.ncbi.nlm.nih.gov/pubmed/28981501>
- 424 48. Maghzi AH, Etemadifar M, Heshmat-Ghahdarijani K, Moradi V, Nonahal S, Ghorbani
425 A, et al. Cigarette smoking and the risk of multiple sclerosis: A sibling case-control
426 study in Isfahan, Iran. *Neuroepidemiology*. 2011 Dec;37(3–4):238–42.
- 427 49. Jafari N, Hoppenbrouwers IA, Hop WCJ, Breteler MMB, Hintzen RQ. Cigarette
428 smoking and risk of MS in multiplex families. *Mult Scler*. 2009;15(11):1363–7.
- 429 50. Asadollahi S, Fakhri M, Heidari K, Zandieh A, Vafae R, Mansouri B. Cigarette
430 smoking and associated risk of multiple sclerosis in the Iranian population. *J Clin
431 Neurosci*. 2013 Dec 1;20(12):1747–50.
- 432 51. Hedström AK, Hillert J, Olsson T, Alfredsson L. Smoking and multiple sclerosis
433 susceptibility. *Eur J Epidemiol*. 2013 Nov;28(11):867–74.
- 434 52. Ghadirian P, Dadgostar B, Azani R, Maisonneuve P. A case-control study of the
435 association between socio-demographic, lifestyle and medical history factors and
436 multiple sclerosis. *Can J Public Heal*. 2001;92(4):281–5.
- 437 53. Mouhieddine TH, Darwish H, Fawaz L, Yamout B, Tamim H, Khoury SJ. Risk factors
438 for multiple sclerosis and associations with anti-EBV antibody titers. *Clin Immunol*.
439 2015 May 1;158(1):59–66.

- 440 54. Patsopoulos NA, Baranzini SE, Santaniello A, Shoostari P, Cotsapas C, Wong G, et al.
441 Multiple sclerosis genomic map implicates peripheral immune cells and microglia in
442 susceptibility. *Science* (80-). 2019 Sep 27;365(6460).
- 443 55. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-
444 Base platform supports systematic causal inference across the human phenome. *Elife*
445 [Internet]. 2018 May 30 [cited 2019 Jan 28];7. Available from:
446 <https://elifesciences.org/articles/34408>
- 447 56. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
448 instruments: effect estimation and bias detection through Egger regression. *Int J*
449 *Epidemiol* [Internet]. 2015 Apr 1 [cited 2019 Jan 28];44(2):512–25. Available from:
450 <https://academic.oup.com/ije/article-lookup/doi/10.1093/ije/dyv080>
- 451 57. Bowden J, Smith GD, Haycock PC, Burgess S. Consistent Estimation in Mendelian
452 Randomization with Some Invalid Instruments Using a Weighted Median Estimator.
453 *Genet Epidemiol* [Internet]. 2016 [cited 2018 Nov 16];40:304–14. Available from:
454 <https://onlinelibrary.wiley.com/doi/pdf/10.1002/gepi.21965>
- 455 58. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian
456 randomization via the zero modal pleiotropy assumption. *Int J Epidemiol* [Internet].
457 2017 Dec 1 [cited 2019 Jan 28];46(6):1985–98. Available from:
458 <https://academic.oup.com/ije/article/46/6/1985/3957932>
- 459 59. Zhao Q, Wang J, Hemani G, Bowden J, Small DS. Statistical inference in two-sample
460 summary-data Mendelian randomization using robust adjusted profile score. 2018 Jan
461 29 [cited 2020 Jan 23]; Available from: <http://arxiv.org/abs/1801.09652>
- 462 60. Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy
463 in causal relationships inferred from Mendelian randomization between complex traits

464 and diseases. Nat Genet [Internet]. 2018 May 23 [cited 2019 Jan 28];50(5):693–8.

465 Available from: <http://www.nature.com/articles/s41588-018-0099-7>


466 61. Lawlor DA, Tilling K, Smith GD. Triangulation in aetiological epidemiology. Int J


467 Epidemiol. 2016 Dec 1;45(6):1866–86.

468

469

470



A**B**